Cerebral Palsy Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Cerebral Palsy Treatment Market is Segmented by Disease Type (Spastic Cerebral Palsy, Dyskinetic Cerebral Palsy, Ataxic Cerebral Palsy, Mixed Cerebral Palsy), Treatment Type (Surgery and Medication), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above-mentioned segments.

Market Snapshot

Cerebral Palsy Treatment Market Size
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: 4.4 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The cerebral palsy treatment market is expected to register a significant CAGR of 4.4% during the study period, 2022-2027.

In recent times, countries have faced a huge threat of COVID-19. As per the World Health Organization (WHO), coronavirus disease is an infectious disease, and most people infected with the COVID-19 virus will experience mild to moderate respiratory illness. COVID-19 has a considerable effect on all major organ systems. The study "Why individuals with cerebral palsy are at higher risk for respiratory complications from COVID-19" published in 2020 stated that respiratory dysfunction is one of the leading causes of morbidity and mortality in individuals with cerebral palsy (CP). Individuals with pre-existing respiratory disorders are at greater risk for respiratory complications if they contract COVID-19, thereby increasing the risk of morbidity associated with cerebral palsy. Due to the COVID-19-led lockdown, there were supply chain disruptions in accessing the treatment for cerebral palsy. The emergence of telemedicine has helped in improving accessibility, significantly impacting the market. According to the study "Accelerating Telemedicine for Cerebral Palsy During the COVID-19 Pandemic and Beyond," published in June 2020, a multidisciplinary therapeutic presence is more accessible with telemedicine, bringing together various specialties and approaches to the child's natural environment. Telemedicine is expected to go beyond the COVID-19 era and will dominate during the study period, impacting the market growth.

The factors propelling the studied market growth are the growing burden of cerebral palsy, rise in investments, technological advancements, government initiatives, and other key strategies adopted by the key market players.

According to the article published by Congress.gov in March 2022, cerebral palsy is the most common motor disability in children, affecting more than 1,000,000 Americans, 1 in 345 children, and over 17,000,000 people worldwide.

The growing research and development activities in the studied market are driving the market growth. For instance, as per clinicaltrials.gov, in January 2022, Neurocrine Biosciences initiated phase 3, a randomized, double-blind, placebo-controlled study to evaluate the efficacy of valbenazine versus placebo in participants aged 6 to 70 years for the treatment of dyskinesia due to cerebral palsy (DCP). The study is expected to be completed by August 2024. Positive responses from such studies evaluating the efficacies of existing treatments for cerebral epilepsy will increase its adoption, thus boosting the studied market during the study period.

Moreover, rising strategic initiatives such as mergers and partnerships by key market players will expand the offerings in the market, which will boost the studied market. For instance, in April 2022, the Japanese subsidiary of Control Bionics signed an exclusive distribution agreement with Double Research and Development Co., Ltd. To start full-scale operations to better solve the communication challenges of people with severe disabilities in Japan through technology. Control Bionics has been working with users living with severe disabilities, including cerebral palsy (CP) and others.

Rising investments in the market will propel technological innovation and expand the geographical presence, which will drive the market. For instance, in April 2022, Jupiter Lifeline Hospitals is planning to set up a state-of-the-art neuro-rehabilitation center in the United Kingdom with an investment of around 50 million pounds. The proposed rehabilitation center in the country is expected to have a 100-bed inpatient capacity, which will benefit patients with stroke, traumatic brain injury, cerebral palsy, spinal cord injury, Parkinson's disease, progressive and non-progressive neurological disorders, and sports injuries.

Therefore, owing to the aforementioned factors, the studied market is expected to grow significantly during the study period. However, the side effects of drugs associated with cerebral palsy are expected to hinder the market growth during the study period.

Scope of the Report

As per the scope of the report, cerebral palsy refers to a group of symptoms that involve difficulty moving and muscle stiffness (spasticity). It results from brain malformations that occur before birth as the brain is developing or from brain damage that occurs before, during, or shortly after birth. The cerebral palsy treatment market is segmented by disease type (spastic cerebral palsy, dyskinetic cerebral palsy, ataxic cerebral palsy, mixed cerebral palsy), treatment type (surgery and medication), and distribution channel (hospital pharmacies, retail pharmacies and online pharmacies) and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above-mentioned segments.

By Disease Type
Spastic Cerebral Palsy
Dyskinetic Cerebral Palsy
Ataxic Cerebral Palsy
Mixed Cerebral Palsy
By Treatment Type
Others (Anti-inflammatories and Stool Softeners)
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Spastic Cerebral Palsy Segment is Expected to Account for the Large Market Share Over the Forecast Period

Spastic cerebral palsy is a developmental disorder caused by damage to the brain before birth, during delivery, or within the first few years of life. This condition prevents the normal development of motor function. Spastic cerebral palsy causes increased muscle tone, stiff muscles, and difficulty walking. Treatments for spastic cerebral palsy include physical therapy, medications, and surgery. The different types of spastic cerebral palsy are spastic diplegia, spastic Hemiplegia, and spastic Quadriplegia.

Factors such as high incidences of spastic cerebral palsy, rising research and development activities, and increasing investments are expected to significantly boost the studied market growth.

According to a March 2022 update of the article “Spastic Cerebral Palsy” published by CerebralPalsyGuidance.com, spastic cerebral palsy is the most common form of cerebral palsy, accounting for 70% to 80% of all people diagnosed. Therefore, due to the high burden of the diseases, there is an increasing demand for its therapeutics, thus boosting the investments and research activities in the segment, thus, contributing to the significant growth of the market.

The growing research activities in the segment will fuel the market. For instance, as per Clinicaltrials.gov, a study was initiated in November 2021 by Supernus Pharmaceuticals Inc. It is a phase 2/3, randomized, double-blind, placebo-controlled, single-treatment, multicenter trial which is used to access the efficacy and safety of MYOBLOC for the treatment of upper limb spasticity in adults followed by an open-label extension safety trial. Positive results from such studies will increase its adoption, thus driving the market.

Moreover, the study “The safety and efficacy of umbilical cord blood mononuclear cells in individuals with spastic cerebral palsy: a randomized double-blind sham-controlled clinical trial” published in March 2022, demonstrated that intrathecal injection of umbilical cord blood mononuclear cell (UCB-MNC) was safe and effective in children with cerebral palsy.

Thus, due to the above-mentioned factors, the studied segment is expected to contribute to the significant growth of the market.

Cerebral Palsy Treatment Market Share

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

The primary driving factors for the growth of the North American cerebral palsy market are the rising burden of cerebral palsy, growing research and development activities, increasing investments, supporting government initiatives, and key initiatives taken by the key market players.

The United States within North America is expected to hold a significant share of the studied market during the study period. For instance, According to the article published by Congress.gov in March 2022, in the United States, more than 10,000 babies are diagnosed with cerebral palsy each year. The high prevalence of cerebral palsy in the country is increasing the demand for its therapeutics. Therefore pharmaceutical companies are investing heavily in the therapeutic area, which will significantly drive the market.

Rising investments in the studied market will bring innovation in the studied market, thereby boosting the accessibility of therapeutics for cerebral palsy, thereby fueling the market. For instance, in March 2022, Adam Boehler, in partnership with Martin Ventures, invested in StationMD, a healthcare company that uses telemedicine to deliver medical care to people with intellectual and developmental disabilities (I/DD). That includes individuals with autism spectrum disorder, Down syndrome, and cerebral palsy. This will increase the accessibility of treatments to people with cerebral palsy, thereby driving the market.

Additionally, in January 2022, Governor of New York Kathy Hochul invested in Cerebral Palsy Associations of New York State. This proposal includes USD 2 billion in workforce funding and USD 500 million in cost of living to support a sustainable care infrastructure and therefore focus on addressing the current workforce crisis.

Moreover, strategic initiatives adopted by key market players creating awareness for cerebral palsy are expected to drive market growth. For instance, in February 2022, Edward R. Matthews, CEO of ADAPT Community Network, and Armando A. Contreras, President, and CEO of United Cerebral Palsy, launched Start Here, a new digital platform that will provide caregivers with a trusted source for guidance on everything from the basics of cerebral palsy and other intellectual and developmental disabilities, as well as managed care advice about how to be an effective advocate for their child. This will create awareness for therapeutics for cerebral palsy, thus increasing its demand, which will lead to lucrative growth of the market.

Therefore, due to the above-mentioned factors, the studied market is expected to lead to lucrative growth of the market in North America.

Cerebral Palsy Treatment Market Growth

Competitive Landscape

The studied market is fragmented and moderately competitive. The strategies such as mergers and acquisitions and partnerships adopted by key market players to expand their geographical reach and product offerings will drive the market growth. The key players in the market are AbbVie Inc., Ipsen Biopharmaceuticals Inc., Merz GmbH & Co. KGaA, Teva Pharmaceutical Industries Ltd, Supernus Pharmaceuticals Inc., and others.

Recent Development

  • In March 2022, Congressman Steve Cohen, with bipartisan co-sponsors Congressmen Brian Fitzpatrick and Emanuel Cleaver, introduced the Cerebral Palsy Research Program Act, which would create a cerebral palsy research program within the Centers for Disease Control and Prevention (CDC) and provide the first-ever dedicated source of federal funding for cerebral palsy research.
  • In February 2022, Cerebral Palsy Alliance Research Foundation (CPA) and Hearts & Minds Investments Limited entered into a significant new partnership, supporting innovative research that aims to revolutionize newborn intensive care around the world. It will support Australia’s leading research and health professionals in neonatology and bioengineering to reduce the incidence and severity of cerebral palsy and other lifelong disabilities in children.

Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Burden of Cerebral Palsy

      2. 4.2.2 Increasing Investments and Advancements by Market Players

    3. 4.3 Market Restraints

      1. 4.3.1 Side Effect Associated With The Drugs

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - in USD Million)

    1. 5.1 By Disease Type

      1. 5.1.1 Spastic Cerebral Palsy

      2. 5.1.2 Dyskinetic Cerebral Palsy

      3. 5.1.3 Ataxic Cerebral Palsy

      4. 5.1.4 Mixed Cerebral Palsy

    2. 5.2 By Treatment Type

      1. 5.2.1 Surgery

      2. 5.2.2 Medication

        1. Anticholinergics

        2. Anticonvulsants

        3. Antidepressants

        4. Antispastic

        5. Others (Anti-inflammatories and Stool Softeners)

    3. 5.3 By Distribution Channel

      1. 5.3.1 Hospital Pharmacies

      2. 5.3.2 Retail Pharmacies

      3. 5.3.3 Online Pharmacies

    4. 5.4 Geography

      1. 5.4.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.4.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 AbbVie Inc.

      2. 6.1.2 Ipsen Biopharmaceuticals Inc.

      3. 6.1.3 Merz GmbH & Co. KGaA

      4. 6.1.4 Teva Pharmaceutical Industries Ltd

      5. 6.1.5 Supernus Pharmaceuticals Inc.

      6. 6.1.6 Proveca Ltd

      7. 6.1.7 Novartis AG

      8. 6.1.8 Revance Therapeutics

      9. 6.1.9 Baylx Inc.

      10. 6.1.10 Hope Biosciences

      11. 6.1.11 Help Therapeutics

      12. 6.1.12 MGC Pharma

    2. *List Not Exhaustive

**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Cerebral Palsy Treatment Market market is studied from 2019 - 2027.

The Global Cerebral Palsy Treatment Market is growing at a CAGR of 4.4% over the next 5 years.

Asia-Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Ipsen Biopharmaceuticals Inc., Merz GmbH & Co. KGaA, Teva Pharmaceutical Industries Ltd., Supernus Pharmaceuticals, Inc., Abbvie Inc. are the major companies operating in Global Cerebral Palsy Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!